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Abstract
Background: Aortic stenosis (AS) induces pressure overload of the left ventricle (LV) and 
results in left ventricular hypertrophy. The remodeling of the LV in patients with AS is a com-
plex process including structural and functional disturbances. After aortic valve replacement, 
reverse remodeling of LV begins. The aim of this study was to evaluate the impact of transcath-
eter aortic valve ımplantation (TAVI) on LV mass (LVM) in early and mid-term follow-ups 
after the procedure.
Methods and Results: We enrolled consecutive 75 patients who underwent successful TAVI. 
Transthoracic echocardiography was performed prior to TAVI and at hospital discharge, in the 
1st month and 6th month of the follow-ups. The mean LV ejection fraction improved significantly 
after TAVI (54.2 ± 15.0% to 57.3 ± 11.7%, p < 0.001). There were no significant changes 
between the baseline and discharge mean LVM and LVM index values (LVMI; p = 0.1). How-
ever, LVMI decreased significantly in the 1st month of follow-up compared to baseline (123.3 ± 
± 20.3 to 127.9 ± 21.3 g/m2, respectively, p < 0.001). Also, significant regression of LVM was 
observed at the 1st month of follow-up compared to baseline (228.3 ± 33.5 g vs. 236.5 ± 34.2 g,  
respectively, p < 0.001). Furthermore, the significant regression in both of LVM and LVMI 
continued at 1st and 6th months of the follow-ups (p < 0.001).
Conclusions: A significant regression of LVM was observed after TAVI. These changes may 
have prognostic value in patients with severe AS. (Cardiol J 2015; 22, 6: 645–650)
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Introduction
Degenerative aortic valve stenosis (AS) is the 
most common valvular heart disease in the elderly 
population and it has an increasing prevalence with 
age [1–3]. AS induces pressure overload of the 
left ventricle (LV) and results in left ventricular 
hypertrophy (LVH). Myocyte degeneration and 
fibrosis have major roles in the pathophysiology 
of hypertrophic remodeling. LVH caused by AS is 
associated with systolic and diastolic dysfunction 
of the LV which are the recognized risk factors of 
cardiac morbidity and mortality [3]. Transcatheter 
aortic valve implantation (TAVI) has been proven to 
be a promising therapy for high risk or inoperable 
patients with AS [4].
Left ventricular remodeling in patients with 
AS is a complex process including structural and 
functional disturbances. After aortic valve re-
placement (AVR), reverse remodeling of the LV 
begins. This way, LV volume and mass regress, 
LV systolic and diastolic function improves. This 
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process seemed to be important for prognosis and 
symptomatic improvement after open surgery 
[5, 6]. The early- and late-term effects of TAVI on LV 
mass (LVM) and volume regression and LV diastolic 
dysfunction have controversial data in the literature. 
The aim of this study was to evaluate the impact 
of TAVI on LVM in early and mid-term follow-ups.
Methods
Patients
We consecutively recruited 75 patients 
who underwent TAVI using balloon-expandable 
Edwards Sapien XT (Edwards Lifesciences, Ir-
vine, CA, USA) prostheses between July 2011 
and July 2013. The study population included 
symptomatic patients with severe AS (mean gra-
dient ≥ 40 mm Hg and/or aortic valve area [AVA] 
< 1 cm2 or indexed AVA ≤ 0.6 cm2/m2) and inop-
erable or at high risk for surgical AVR (s-AVR) 
due to co-morbid conditions. The exclusion criteria 
were as follows: any contraindications to anticoagu-
lant and/or antiplatelet agents, life expectancy with 
or without AVR < 12 months, non-calcified valve, 
history of AVR, severe aortic or mitral regurgita-
tion, severe renal insufficiency, coagulopathy or 
bleeding diathesis and abdominal aortic aneurysm. 
Before the procedure, all patients underwent tran-
sthoracic echocardiography (TTE), transesopha-
geal echocardiography (TEE), multislice computed 
tomography (MSCT) and coronary angiography. 
Pretreatment operative risk was assessed by the 
Logistic European System for Cardiac Operative 
Risk Evaluation (EuroSCORE) and the Society of 
Thoracic Surgeons (STS) score.
All patients were informed before the proce-
dure, and the study was approved by our hospital’s 
ethics committee.
Transthoracic echocardiography
All patients underwent TTE (IE33 echo-
cardiography system, Philips Medical Systems, 
Eindhoven, the Netherlands) with an experienced 
operator. TTE Doppler and 2-dimensional images 
were obtained from parasternal short and long axis, 
apical 4-chamber, and subcostal 4-chamber views. 
TTE was reviewed to assess the valve morphology, 
valvular anatomy, aortic annulus diameter, ventric-
ular function, and pericardium. It was performed 
prior to TAVI and at hospital discharge, in the 
1st month and 6th months of the follow-ups.
The Doppler echocardiographic measurements 
included LV end-diastolic volume, LV ejection frac-
tion (LVEF) calculated with the modified Simpson’s 
method, transvalvular pressure gradient deter-
mined by the Bernoulli formula, and AVA calculated 
by the continuity equation. Patients with low flow 
and low gradient AS underwent dobutamine stress 
echocardiography in order to determine the exact 
severity of AS and LV contractile reserve. LVM 
was calculated with the formula as follows: LVM = 
0.8 × (1.04 × [(LVEDD + LVPWTd + LVSWTd)3 
+ (LVEDD)3]) + 0.6 g [7], where LVEDD is left 
ventricular end diastolic diameter; LVPWTd — left 
ventricular posterior wall thickness diameter, and 
LVSWTd — left ventricular septal wall thickness 
diameter. LVM index (LVMI) was determined by 
using the formula, LVM/body surface area [g/m2]. 
LVH was defined as LVMI > 95 g/m2 for women and 
LVMI > 115 g/m2 for men. All echocardiographic 
parameters were evaluated according to guidelines 
of the American Society of Echocardiography [8].
Transcatheter aortic valve implantation
TAVI was performed at the catheterization 
laboratory with fluoroscopy using conventional 
technique. Seventy-two (96%) through femoral ar-
tery and 3 (4%) patients through subclavian artery 
received a balloon expandable Edwards Sapien XT 
(Edwards Lifesciences, Irvine, CA, USA) aortic 
valve. The sizes of the valves used were 23 mm, 
26 mm and 29 mm. It was decided with combined mul-
timodal imaging methods like TTE, TEE and MCST.
Statistical analysis
All analyses were performed using SPSS 
version 19.0 (IBM Corporation, Armonk, NY). 
Continuous variables are presented as mean, 
standard deviation (SD) and were compared by 
means of a 2-sided students T-test. Categorical 
data were expressed as frequency (percentages) 
and compared using the c2 and Fisher’s exact tests. 
Echocardiographic data obtained at baseline; dis-
charge, 1st month and 6th month were compared by 
repeated measures ANOVA. Continuous variables 
were compared between patients before and after 
TAVI using the paired Student’s t-test (for normally 
distributed variables) or the Wilcoxon test (for 
not-normally distributed variables). Significance 
was accepted as p < 0.05.
Results
Patients
Demographic and clinical characteristics of 
the study population were presented in Table 1. 
The mean age of the patients was 77.8 ± 7.8 years. 
Thirty-eight point seven percent of the patients 
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were male, whereas 61.3% were female. According 
to New York Heart Association classification, 93% of 
the patients were in functional class III and IV (Fig. 1). 
Past history revealed coronary artery disease in 
70%, hypertension in 82%, diabetes mellitus in 
27%, and peripheral artery disease in 34% of the 
patients. The STS score of the patients was 7.3 ± 
± 5.2% and mean logistic EuroSCORE was 21.8 ± 
± 16.5%. According to the SURTAVI risk model, 
90.6% of patients were in the moderate and high 
risk groups.
Transcatheter aortic valve implantation
TAVI was performed with conventional tech-
nique under general (42 patients) and local an-
esthesia (33 patients). Acute procedural success 
rate was 100%. In all subjects, balloon-expandable 
Edwards Sapien XT (Edwards Lifesciences, Irvine, 
CA, USA) valve was deployed through femoral 
(72 patients) and subclavian artery (3 patients) 
route. Three valve sizes of 23 mm, 26 mm and 
29 mm were available. Patients were heparinized 
during the procedure to achieve an activated clot-
ting time of 250–300 s and all procedures were 
performed successfully. For access site closure, 
vascular closure devices were used in 72 patients 
while surgical closure was used in the remaining 
patients. Stable patients were discharged from the 
hospital and follow-ups at 1st and 6th months were 
planned. During the follow-ups, routine physical 
examinations, TTE and functional capacities were 
evaluated.
TAVI was performed by a 100% procedural 
success rate. However, a second valve has been 
required in 2 patients, first due to the lower locali-
Table 1. Basal characteristics and procedural 
features.
Patient characteristics All patients (n = 75)
Male/female 38.7%/61.3%
Age [year] 77.8 ± 7.8
Body mass index [kg/m2] 27.6 ± 5.2
NYHA II 8%
NYHA III 64%
NYHA IV 28%
STS 7.4 ± 5.6
SURTAVI:
Low risk 9.3%
Moderate risk 33.3%
High risk 57.3%
EuroScore [%] 21.8 ± 16.5
Associated comorbid conditions
Coronary artery disease 72.0%
Hypertension 81.3%
Diabetes mellitus 26.7%
Hyperlipidemia 45.3%
Smoker 20.0%
COPD:
Mild 44.0%
Moderate 30.7%
Severe 22.7%
Peripheral arterial disease 30.7%
Atrial fibrillation 28.0%
Echocardiographic variables
LVEDD [cm] 4.67 ± 0.7
LVESD [cm] 3.05 ± 0.9
IVS (cm) 1.33 ± 0.2
Posterior wall thickness [cm] 1.27 ± 0.1
Maximal gradient [mm Hg] 87.5 ± 23.2
Mean gradient [mm Hg] 53.3 ± 14.8
Aortic valve area [cm2] 0.6 ± 0.1
LVEF [%] 54.2 ± 15.1
Peak SPAP [mm Hg] 47.2 ± 14.4
Aortic regurgitation:
Mild 54.6%
Moderate 5.3%
Severe 1.3%
Mitral regurgitation:
Mild 56.0%
Moderate 6.7%
Severe 1.3%
Femoral vascular closure 85.5%
Local anesthesia 80%
Valve diameter [mm]:
23 40%
26 33%
29 2%
Contrast used [cc] 201.5 ± 55.7
Duration of discharge  
after procedure [day]
7.3 ± 5.3
NYHA — New York Heart Association; STS — Society of Thoracic 
Surgeons, COPD — chronic obstructive pulmonary disease;  
LVEDD — left ventricular end diastolic diameter; LVESD — left ven-
tricular end systolic diameter; IVS — interventricular septum thick-
ness; LVEF — left ventricular ejection fraction; SPAP — systolic 
pulmonary artery pressure
Figure 1. Changing functional capacity after transcath-
eter aortic valve implantation; NYHA — New York Heart 
Association.
www.cardiologyjournal.org 647
Hacı Ahmet Kasapkara et al., Impact of TAVI on the left ventricular mass
zation and second due to valve embolization. After 
the procedure, totally 5 in-hospital mortalities 
were recognized because of the right ventricular 
rupture due to rapid pacing (in 2 patients), LV rup-
ture due to wire in the LV, postoperative bleeding 
via supra-aortic approach and left main coronary 
artery obstruction due to the shift of aortic cusp 
calcification.
Transthoracic echocardiography results  
before and after the procedure
Transthoracic echocardiographic parameters 
at baseline and during follow-ups were shown in 
Table 2. Clinical follow-ups of all patients were 
done in our hospital. All patients had severe AS 
with a mean AVA of 0.62 ± 0.17 cm2 and average 
mean aortic valve gradient of 53.3 ± 14.8 mm Hg. 
Mean baseline LVEF was 54.2 ± 15.1%.
Significant hemodynamic improvement has 
been observed after TAVI. Mean transvalvu-
lar aortic valve gradient decreased significantly 
from 53.3 ± 14.8 mm Hg to 9.22 ± 3.33 mm Hg, 
(p < 0.001). Also, a statistically significant increase 
was observed in LVEF compared to baseline 
at discharge, and in the 1st and 6th months of follow-
ups (54.2 ± 15.0% vs. 57.3 ± 11.7% vs. 59.5 ± 
± 8.4% vs. 61.1 ± 6.7%, respectively, p < 0.001). 
Both LVM and LVMI values decreased at discharge 
compared with baseline, but these did not reach 
statistical significance with value of p = 0.10 and 
p = 0.12, respectively. At 1st month, LVM (228.3 ± 
± 22.9 g vs. 236.5 ± 34.2 g, respectively, p < 0.001) 
and LVMI (123.3 ± 20.3 g/m2 vs 127.9 ± 21.3 g/m2, 
respectively, p < 0.001) reduced significantly com-
pared with baseline and also these regressions con-
tinued and reached the statistical significance at the 
6th month of follow-up (p < 0.001) (Table 2, Fig. 2). 
During the 6th month of the follow-up, it was detect-
ed that diastolic diameter of LV posterior wall thick-
ness regressed significantly from 1.27 ± 0.1 mm 
to 1.20 ± 0.1 mm (p < 0.001) in addition to inter-
ventricular septum diastolic wall thickness which 
regressed from 1.33 ± 0.1 mm to 1.27 ± 0.1 mm 
(p = 0.01).
Echocardiographic follow-ups were achieved in 
95% and 85% of patients at 1st month and 6th month, 
respectively. A statistically significant improvement 
has been monitored in valve functions (mean gradi-
ent, AVA) at discharge and follow-ups after TAVI. 
There was no severe paravalvular aortic regurgita-
tion in any patients after TAVI and at follow-ups. 
Only 4 (3.8%) patients required permanent pace-
maker because of complete atrioventricular block. 
The length of mean hospital stay was 7.3 ± 5.3 days.Ta
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Discussion
Degenerative AS is one of the most common 
acquired valvular heart diseases. The mortality 
rate, especially in older patients, related to severe 
AS is high. The excessive pressure overload in-
duced by AS results in LVH which in turn leads to 
an increased risk of heart failure, cerebrovascular 
accident and sudden cardiac death [9]. Therefore, 
the prognosis of patients with symptomatic AS 
accompanying severe LVH is worse.
Increase in LVM is an independent risk factor 
for adverse cardiovascular events and mortality 
[10, 11]. LVMI is an index used in the evaluation 
of LVH. It is known that, LVMI decreases with 
the reduction of LV afterload after s-AVR and as 
a result, improvement in myocardial ischemia, 
functional capacity and long-term prognosis is 
observed [12, 13]. The regression in LVMI after s-
AVR is believed to be more important than valvular 
gradient as a prognostic factor [14–16]. The rate 
and magnitude of regression in LVMI can also be 
used as a distinctive parameter for reverse cardiac 
remodeling [17]. The decline of LVMI after s-AVR 
can differ depending on variables such as patient’s 
age, prosthesis size, valvular gradient, patient-
prosthesis mismatch and surgical method. The 
long-term outcomes have been demonstrated to be 
better in patients showing rapid regression in LVH 
after surgery compared to others. In a vast majority 
of study, it was demonstrated that the regression of 
LVM after s-AVR is chiefly observed in the 1st year 
and, generally, the final measurement of regression 
in LVM is accepted to be reached approximately in 
the first 6 months of follow-ups [16, 18–20].
In our study, we assessed the regression of 
LVH with the help of LVMI measured by echocar-
diography at discharge and in the 1st and 6th months 
after TAVI. LVMI was observed to be decreased 
significantly at 1st month after the procedure and 
during the clinical follow-ups compared to base-
line values. Therefore, it can be propounded that 
the regression in LVMI and thus LVH after TAVI 
commences earlier and sustains during the clinical 
follow-ups compared to conventional s-AVR and 
thus will be able to reach the final values earlier. 
Here if we compare the conventional surgery with 
TAVI, we can observe that, due to the cardiopul-
monary bypass, the early stage of hemodynamic 
effects depending on myocardial ischemia, myo-
cardial edema and ischemia-reperfusion injury can 
be worse in the surgical method. The impaired 
diastolic functions depending on these causes 
can be associated with peri-operative adverse 
outcomes, especially in older patients [21, 22]. In 
a study comparing the TAVI and s-AVR in patients 
with AS, performed by Guarracino et al. [22], acute 
improvement observed in diastolic functions after 
TAVI had not been detected after s-AVR. They 
explained this by the impediment of the reduction 
in afterload due to the cardioplegia and cardiopul-
monary bypass after s-AVR [22]. Gonçalves et al. 
[23] have showed the reduction of LV end-diastolic 
pressure with an invasive method just a minute 
after TAVI and detected this without any change 
in echocardiographic E/É’ratio [23].
Figure 2. Changing left ventricular mass (LVM) and left ventricular mass index (LVMI) with transcatheter aortic valve 
implantation.
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Impaired LV diastolic function is an independ-
ent risk factor for early- and late-term mortality 
in patients with AS after s-AVR. AS leads to an 
increase in LV myocyte mass and additionally 
interstitial fibrosis. The regression of interstitial 
fibrosis can last long and normalization of diastolic 
functions can take a long time.
TAVI is performed in the older patients with 
high surgical risk and multiple co-morbid clinical 
conditions. Due to the early favorable hemody-
namic effects and the retrieval of patients from car-
diopulmonary bypass, it is believed to be superior 
compared with s-AVR. As it is shown in our study, 
the decrease in LVMI, which is the indicator of 
LVH in the early period and follow-ups after TAVI, 
can imply the usefulness and reliability of TAVI in 
patients with older age and co-morbid diseases.
Limitations of the study
The main limitation of our study was a small 
number of patients. The main reason of limited 
number of patients included into this study is the 
rarity of patients with AS convenient for TAVI. 
Therefore, larger scale studies are needed to 
confirm the beneficial effect of TAVI on LVH. The 
second issue is, although all echocardiographic 
examinations were performed by an experienced 
single operator, LVM measurement might be af-
fected by some potential errors.
Conclusions
Our study demonstrated that TAVI is asso-
ciated with a significant improvement on LVMI 
which is associated with LVH both in early period 
and follow-ups. TAVI is comparable to s-AVR in 
terms of LV reverse remodeling and superior to 
it due to the early favorable hemodynamic effects 
and the retrieval of patients from cardiopulmonary 
by-pass. TAVI significantly reduces the trans-aortic 
gradients and increases LVEF at discharge, and in 
the 1st and 6th months of follow-ups as well.
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